Exact Mass: 505.2213
Exact Mass Matches: 505.2213
Found 500 metabolites which its exact mass value is equals to given mass value 505.2213
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Amprenavir
Amprenavir is only found in individuals that have used or taken this drug. It is a protease inhibitor used to treat HIV infection.Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Benidipine
Triletide
Asp Thr Arg Asp
Glu Ser Arg Asp
Arg Asp Thr Asp
Rocaglamide
Rocaglamide is an organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity. It has a role as a metabolite, an antineoplastic agent and an antileishmanial agent. It is an organic heterotricyclic compound, a monomethoxybenzene and a monocarboxylic acid amide. Rocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides. Rocaglamides are secondary metabolites of the plant genus Aglaia, and extracts of the plant have traditionally been used as a form of insect repellant due to its natural insecticidal properties. Reports of Aglaia anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species A. elliptifolia. Rocaglamide and a number of its derivatives (e.g. [didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of certain chemotherapy-resistant cancers. Rocaglamide is a natural product found in Aglaia rimosa, Aglaia elliptifolia, and other organisms with data available. An organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity.
Amprenavir
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Benidipine
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Ala Glu Met Arg
Ala Glu Arg Met
Ala Glu Thr Trp
Ala Glu Trp Thr
Ala Met Glu Arg
Ala Met Arg Glu
Ala Arg Glu Met
Ala Arg Met Glu
Ala Thr Glu Trp
Ala Thr Trp Glu
Ala Trp Glu Thr
Ala Trp Thr Glu
Cys Asp Ile Arg
Cys Asp Leu Arg
Cys Asp Arg Ile
Cys Asp Arg Leu
Cys Glu Arg Val
Cys Glu Val Arg
Cys Ile Asp Arg
Cys Ile Arg Asp
Cys Lys Gln Gln
Cys Leu Asp Arg
Cys Leu Arg Asp
Cys Met Pro Arg
Cys Met Arg Pro
Cys Pro Met Arg
Cys Pro Arg Met
Cys Gln Lys Gln
Cys Gln Gln Lys
Cys Arg Asp Ile
Cys Arg Asp Leu
Cys Arg Glu Val
Cys Arg Ile Asp
Cys Arg Leu Asp
Cys Arg Met Pro
Cys Arg Pro Met
Cys Arg Val Glu
Cys Val Glu Arg
Cys Val Arg Glu
Asp Cys Ile Arg
Asp Cys Leu Arg
Asp Cys Arg Ile
Asp Cys Arg Leu
Asp Asp Arg Thr
Asp Asp Thr Arg
Asp Glu Arg Ser
Asp Glu Ser Arg
Asp Phe Pro Gln
Asp Phe Gln Pro
Asp Ile Cys Arg
Asp Ile Met Gln
Asp Ile Gln Met
Asp Ile Arg Cys
Asp Leu Cys Arg
Asp Leu Met Gln
Asp Leu Gln Met
Asp Leu Arg Cys
Asp Met Ile Gln
Asp Met Leu Gln
Asp Met Gln Ile
Asp Met Gln Leu
Asp Pro Phe Gln
Asp Pro Gln Phe
Asp Gln Phe Pro
Asp Gln Ile Met
Asp Gln Leu Met
Asp Gln Met Ile
Asp Gln Met Leu
Asp Gln Pro Phe
Asp Arg Cys Ile
Asp Arg Cys Leu
Asp Arg Asp Thr
Asp Arg Glu Ser
Asp Arg Ile Cys
Asp Arg Leu Cys
Asp Arg Ser Glu
Asp Arg Thr Asp
Asp Ser Glu Arg
Asp Ser Arg Glu
Asp Ser Val Trp
Asp Ser Trp Val
Asp Thr Asp Arg
Asp Val Ser Trp
Asp Val Trp Ser
Asp Trp Ser Val
Asp Trp Val Ser
Glu Ala Met Arg
Glu Ala Arg Met
Glu Ala Thr Trp
Glu Ala Trp Thr
Glu Cys Arg Val
Glu Cys Val Arg
Glu Asp Arg Ser
Glu Asp Ser Arg
Glu Phe Asn Pro
Glu Phe Pro Asn
Glu Ile Met Asn
Glu Ile Asn Met
Glu Leu Met Asn
Glu Leu Asn Met
Glu Met Ala Arg
Glu Met Ile Asn
Glu Met Leu Asn
Glu Met Asn Ile
Glu Met Asn Leu
Glu Met Gln Val
Glu Met Arg Ala
Glu Met Val Gln
Glu Asn Phe Pro
Glu Asn Ile Met
Glu Asn Leu Met
Glu Asn Met Ile
Glu Asn Met Leu
Glu Asn Pro Phe
Glu Pro Phe Asn
Glu Pro Asn Phe
Glu Gln Met Val
Glu Gln Val Met
Glu Arg Ala Met
Glu Arg Cys Val
Glu Arg Asp Ser
Glu Arg Met Ala
Glu Arg Ser Asp
Glu Arg Val Cys
Glu Ser Asp Arg
Glu Thr Ala Trp
Glu Thr Trp Ala
Glu Val Cys Arg
Glu Val Met Gln
Glu Val Gln Met
Glu Val Arg Cys
Glu Trp Ala Thr
Glu Trp Thr Ala
Phe Asp Pro Gln
Phe Asp Gln Pro
Phe Glu Asn Pro
Phe Glu Pro Asn
Phe Gly Pro Trp
Phe Gly Trp Pro
Phe Asn Glu Pro
Phe Asn Pro Glu
Phe Pro Asp Gln
Phe Pro Glu Asn
Phe Pro Gly Trp
Phe Pro Asn Glu
Phe Pro Gln Asp
Phe Pro Trp Gly
Phe Gln Asp Pro
Phe Gln Pro Asp
Phe Trp Gly Pro
Phe Trp Pro Gly
Gly Phe Pro Trp
Gly Phe Trp Pro
Gly Pro Phe Trp
Gly Pro Trp Phe
Gly Trp Phe Pro
Gly Trp Pro Phe
Ile Cys Asp Arg
Ile Cys Arg Asp
Ile Asp Cys Arg
Ile Asp Met Gln
Ile Asp Gln Met
Ile Asp Arg Cys
Ile Glu Met Asn
Ile Glu Asn Met
Ile Met Asp Gln
Ile Met Glu Asn
Ile Met Asn Glu
Ile Met Gln Asp
Ile Asn Glu Met
Ile Asn Met Glu
Ile Gln Asp Met
Ile Gln Met Asp
Ile Arg Cys Asp
Ile Arg Asp Cys
Lys Cys Gln Gln
Lys Met Asn Asn
Lys Asn Met Asn
Lys Asn Asn Met
Lys Gln Cys Gln
Lys Gln Gln Cys
Leu Cys Asp Arg
Leu Cys Arg Asp
Leu Asp Cys Arg
Leu Asp Met Gln
Leu Asp Gln Met
Leu Asp Arg Cys
Leu Glu Met Asn
Leu Glu Asn Met
Leu Met Asp Gln
Leu Met Glu Asn
Leu Met Asn Glu
Leu Met Gln Asp
Leu Asn Glu Met
Leu Asn Met Glu
Leu Gln Asp Met
Leu Gln Met Asp
Leu Arg Cys Asp
Leu Arg Asp Cys
Met Ala Glu Arg
Met Ala Arg Glu
Met Cys Pro Arg
Met Cys Arg Pro
Met Asp Ile Gln
Met Asp Leu Gln
Met Asp Gln Ile
Met Asp Gln Leu
Met Glu Ala Arg
Met Glu Ile Asn
Met Glu Leu Asn
Met Glu Asn Ile
Met Glu Asn Leu
Met Glu Gln Val
Met Glu Arg Ala
Met Glu Val Gln
Met Ile Asp Gln
Met Ile Glu Asn
Met Ile Asn Glu
Met Ile Gln Asp
Met Lys Asn Asn
Met Leu Asp Gln
Met Leu Glu Asn
Met Leu Asn Glu
Met Leu Gln Asp
Met Asn Glu Ile
Met Asn Glu Leu
Met Asn Ile Glu
Met Asn Lys Asn
Met Asn Leu Glu
Met Asn Asn Lys
Met Pro Cys Arg
Met Pro Arg Cys
Met Gln Asp Ile
Met Gln Asp Leu
Met Gln Glu Val
Met Gln Ile Asp
Met Gln Leu Asp
Met Gln Val Glu
Met Arg Ala Glu
Met Arg Cys Pro
Met Arg Glu Ala
Met Arg Pro Cys
Met Val Glu Gln
Met Val Gln Glu
Met Trp Ala Val
Met Trp Gly Ile
Met Trp Gly Leu
Met Trp Ile Gly
Met Trp Leu Gly
Met Trp Val Ala
Asn Glu Phe Pro
Asn Glu Ile Met
Asn Glu Leu Met
Asn Glu Met Ile
Asn Glu Met Leu
Asn Glu Pro Phe
Asn Phe Glu Pro
Asn Phe Pro Glu
Asn Ile Glu Met
Asn Ile Met Glu
Asn Lys Met Asn
Asn Lys Asn Met
Asn Leu Glu Met
Asn Leu Met Glu
Asn Met Glu Ile
Asn Met Glu Leu
Asn Met Ile Glu
Asn Met Lys Asn
Asn Met Leu Glu
Asn Met Asn Lys
Asn Asn Lys Met
Asn Asn Met Lys
Asn Pro Glu Phe
Asn Pro Phe Glu
Pro Cys Met Arg
Pro Cys Arg Met
Pro Asp Phe Gln
Pro Asp Gln Phe
Pro Glu Phe Asn
Pro Glu Asn Phe
Pro Phe Asp Gln
Pro Phe Glu Asn
Pro Phe Gly Trp
Pro Phe Asn Glu
Pro Phe Gln Asp
Pro Phe Trp Gly
Pro Gly Phe Trp
Pro Gly Trp Phe
Pro Met Cys Arg
Pro Met Arg Cys
Pro Asn Glu Phe
Pro Asn Phe Glu
Pro Gln Asp Phe
Pro Gln Phe Asp
Pro Arg Cys Met
Pro Arg Met Cys
Pro Trp Phe Gly
Pro Trp Gly Phe
Gln Cys Lys Gln
Gln Cys Gln Lys
Gln Asp Phe Pro
Gln Asp Ile Met
Gln Asp Leu Met
Gln Asp Met Ile
Gln Asp Met Leu
Gln Asp Pro Phe
Gln Glu Met Val
Gln Glu Val Met
Gln Phe Asp Pro
Gln Phe Pro Asp
Gln Ile Asp Met
Gln Ile Met Asp
Gln Lys Cys Gln
Gln Lys Gln Cys
Gln Leu Asp Met
Gln Leu Met Asp
Gln Met Asp Ile
Gln Met Asp Leu
Gln Met Glu Val
Gln Met Ile Asp
Gln Met Leu Asp
Gln Met Val Glu
Gln Pro Asp Phe
Gln Pro Phe Asp
Gln Gln Cys Lys
Gln Gln Lys Cys
Gln Val Glu Met
Gln Val Met Glu
Arg Ala Glu Met
Arg Ala Met Glu
Arg Cys Asp Ile
Arg Cys Asp Leu
Arg Cys Glu Val
Arg Cys Ile Asp
Arg Cys Leu Asp
Arg Cys Met Pro
Arg Cys Pro Met
Arg Cys Val Glu
Arg Asp Cys Ile
Arg Asp Cys Leu
Arg Asp Asp Thr
Arg Asp Glu Ser
Arg Asp Ile Cys
Arg Asp Leu Cys
Arg Asp Ser Glu
Arg Glu Ala Met
Arg Glu Cys Val
Arg Glu Asp Ser
Arg Glu Met Ala
Arg Glu Ser Asp
Arg Glu Val Cys
Arg Ile Cys Asp
Arg Ile Asp Cys
Arg Leu Cys Asp
Arg Leu Asp Cys
Arg Met Ala Glu
Arg Met Cys Pro
Arg Met Glu Ala
Arg Met Pro Cys
Arg Pro Cys Met
Arg Pro Met Cys
Arg Ser Asp Glu
Arg Ser Glu Asp
Arg Thr Asp Asp
Arg Val Cys Glu
Arg Val Glu Cys
Ser Asp Glu Arg
Ser Asp Arg Glu
Ser Asp Val Trp
Ser Asp Trp Val
Ser Glu Asp Arg
Ser Glu Arg Asp
Ser Arg Asp Glu
Ser Arg Glu Asp
Ser Val Asp Trp
Ser Val Trp Asp
Ser Trp Asp Val
Ser Trp Val Asp
Thr Ala Glu Trp
Thr Ala Trp Glu
Thr Asp Asp Arg
Thr Asp Arg Asp
Thr Glu Ala Trp
Thr Glu Trp Ala
Thr Arg Asp Asp
Thr Trp Ala Glu
Thr Trp Glu Ala
Val Ala Met Trp
Val Ala Trp Met
Val Cys Glu Arg
Val Cys Arg Glu
Val Cys Val Trp
Val Cys Trp Val
Val Asp Ser Trp
Val Asp Trp Ser
Val Glu Cys Arg
Val Glu Met Gln
Val Glu Gln Met
Val Glu Arg Cys
Val Met Ala Trp
Val Met Glu Gln
Val Met Gln Glu
Val Met Trp Ala
Val Gln Glu Met
Val Gln Met Glu
Val Arg Cys Glu
Val Arg Glu Cys
Val Ser Asp Trp
Val Ser Trp Asp
Val Val Cys Trp
Val Trp Asp Ser
Val Trp Ser Asp
Trp Ala Glu Thr
Trp Ala Thr Glu
Trp Asp Ser Val
Trp Asp Val Ser
Trp Glu Ala Thr
Trp Glu Thr Ala
Trp Phe Gly Pro
Trp Phe Pro Gly
Trp Gly Phe Pro
Trp Gly Pro Phe
Trp Pro Phe Gly
Trp Pro Gly Phe
Trp Ser Asp Val
Trp Ser Val Asp
Trp Thr Ala Glu
Trp Thr Glu Ala
Trp Val Asp Ser
Trp Val Ser Asp
3-(4-(N-Biotinoyl-6-aminocaproyloxy)phenyl)propionic acid
(11ar)-(+)-10,11,12,13-tetrahydrodiindeno[7,1-de:1,7-fg][1,3,2]dioxaphosphocin-5-bis(r)-1phenylethyl]amine
(1-[(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-METHYL]-CYCLOHEXYL)-ACETICACID
Methylstat
Methylstat is a potent histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53 and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis[1][2].
methyl (3R,5S,7R,9R,10R)-10-[(2R,3E,5E,7Z)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-7-hydroxy-3,5,9-trimethyl-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylate
5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
N-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
(3S)-3-[[[(2S)-1-[(2S)-2-[[(4-amino-3-chlorophenyl)-oxomethyl]amino]-3,3-dimethyl-1-oxobutyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-cyanopropanoic acid ethyl ester
5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-3,4-dihydropyridine-3,5-dicarboxylate
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[[(2R,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2S,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
4-methoxy-N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[[(2S,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3R)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
BAN ORL 24
BAN ORL 24 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 has antagonistic effect for nociceptin (NOP) receptor with KI value of 0.24 nM in CHO cell. BAN ORL 24 can be used for the research of cancer and analgesic[1].